• 中国科技论文统计源期刊
  • 中国科技核心期刊
  • 中国高校优秀期刊
  • 安徽省优秀科技期刊

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

结核病DNA疫苗研究进展

薛玉芹 方强

引用本文:
Citation:

结核病DNA疫苗研究进展

    作者简介: 薛玉芹(1985-),女,硕士研究生.
  • 基金项目:

    国家自然科学基金项目(30600518/C030112)

  • 中图分类号: R378.91

  • [1] Global tuberculosis Control WHO Report(2012)[R].Geneva:WHO,2012.
    [2] 吴雪琼.新型结核病疫苗的研究现状与发展趋势[J].中国防痨杂志,2012,34(3):133.
    [3] WOLFF JA,WILLIAMS P,ACSADI G,et al.Direct gene transfer into mouse muscle in vivo[J].Science,1990,247(4949 pt 1):1465.
    [4] FLYNN JL,GOLDSTEIN MM,TRIEBOLD KJ,et al Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection[J].Proc Natl Acad Sci USA,1992,89(24):12013.
    [5] VAN PINXTEREN LA,CASSIDY JP,SMEDEGAARD BH,et al.Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells[J].Eur J Immunol,2000,30(12):3689.
    [6] HOHN H,KORTSIK C,ZEHBE I,et al.MHC class II tetramer guided detection of Mycobacterium tuberculosis-specific CD4+ T cells in peripheral blood from patients with pulmonary tuberculosis[J].Scand J Immunol,2007,65(5):467.
    [7] KAUFMANN SHE.Novel tuberculosis vaccination strategies based on under standing the immune response(Foresight)[J].J Intern Med,2010,267(4):337.
    [8] 闻玉梅.治疗性疫苗研究现状与前景[J].生物产业技术,2009:1.
    [9] 梁艳,吴雪琼,李忠明,等.结核分枝杆菌Ag85A/ESAT-6嵌合型质粒DNA疫苗和抗结核药物联合治疗小鼠耐药结核病的效果研究[J].中国防痨杂志,2007,29(5):382.
    [10] 梁艳,吴雪琼,李忠明,等.结核分枝杆菌Ag85A DNA疫苗抗结核作用的研究[J].中国防痨杂志,2012,34(3):181.
    [11] OKADA M,KITA Y,NAKAJIMA T,et al.Novel prophylactic and therapeutic vaccine against tuberculosis[J].Vaccine,2009,27(25/26):3267.
    [12] CHANGHONG S,HAI Z,LIMEI W,et al.Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene[J].Tuberculosis,2009,89(1):54.
    [13] SCHUCK SD,MUELLER H,KUNITZ F,et al.Identification of T-cell antigens specific for latent Mycobacterium tuberculosis infection[J].PLoS One,2009,4(5):e5590.
    [14] MUELLER H,DETJEN AK,SCHUCK SD,et al.Mycobacterium tuberculosis-specific CD4+,IFN IFNγ+,and TNFα+ multifunctional memory T cells coexpress GM-CSF[J].Cyt Okine,2008,43(2):143.
    [15] KAUFMANN SH.Recent findings in immunology give tuberculosis vaccines a new boost[J].Trends Immunol.2005,26(12):660.
    [16] KHERA A,SINGH R,SHAKILA H,et al.Elicitation of efficient,protective immune responses by using DNA vaccines against tuberculosis[J].Vaccine,2005,23(48/49):5655.
    [17] AAGAARD C,HOANG T,DIETRICH J,et al.A multistage tuberculosis vaccine that confers efficient protection before and after exposure[J].Nat Med,2011,17(2):189.
    [18] ANDERSEN P,ROSENKRANDS I,STRYHN A.Use of one or more polypeptides or their fragments,which are expressed during the latent stage of the mycobacterial infection,and/or nucleicacids encoding the polypeptides,fora therapeutic vaccine against tuberculosis:WO,2004006952-A2;US,2004057963-A1;AU,2003242504-A1;EP,1523331-A2;AU,2003242504-A8[P/OL].
    [19] CHANGHONG S,HAI Z,LIMEI W,et al.Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene[J].Tuberculosis,2009,89(1):54.
    [20] 胡方靖,武军驻.pIHsp65GM的构建及其对结核分枝杆菌感染小鼠的保护[J].免疫学杂志,2011,27(8):666.
    [21] LOWRIE DB,TASCON RE,BONATO VL,et al.Therapy of tuberculosis in mice by DNA vaccination[J].Nature,1999,400(6741):269.
    [22] 史小玲,李晖,钟森,等.Hsp70/CD80嵌合DNA疫苗对结核杆菌的治疗作用[J].中华传染病杂志,2004,22(1):30.
    [23] MALIN AS,HUYGEN K,CONTENT J,et al.Vaccinia expression of Mycobacterium tuberculosis-secreted proteins:tissue plasminogen activator signal sequence enhances expression and immunogenicity of M.tuberculosis Ag85[J].Microbes Infect,2000,2(14):1677.
    [24] HA SJ,JEON BY,KIM SC,et al.Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis[J].Gene Ther,2003,10(18):1592.
    [25] LIANG Y,WU X,ZHANG J,et al.The treatment of mice infected with multi-drug-resistant Mycobacterium tuberculosis using DNA vaccines or in combination with rifampin[J].Vaccine,2008,26(35):4536.
    [26] KAMATH AT,FENG CG,MACDONALD M,et al.Differential protective efficacy of DNA vaccine expressing secreted proteins of Mycobacterium tuberculosis[J].Infect Immunol,1999,67(4):1702.
    [27] 吴雪琼,郑越,徐燕杰,等.不同剂量结核病DNA疫苗及细胞因子联合免疫的研究[J].中国免疫学杂志,2006,22(10):883.
    [28] TANGHE A,LEFEVRE P,DENIS O,et al.Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors[J].Immunol,1999,162(2):1113.
    [29] KUMAR M,MEENAKSHI N,SUNDARAMURTHI JC,et al.Immune response to Mycobacterium tuberculosis specific antigen ESAT-6 among south Indian[J].Tuberculosis(Edinb),2010,90(1):60.
    [30] ZHANG H,PENG P,MIAO S,et al.Recombinant Mycobacterium smegmatis expressing an ESAT6-CFP10 fusion protein induces anti-mycobacterial immune responses and protects against Mycobacterium tuberculosis challenge in mice[J].Scand J Immunol,2010,72(4):349.
    [31] WOODWORTH JS,FORTUNE SM,BEHAR SM.Bacterial protein secretion is required for priming of CD8+T cells specific for the Mycobacterium tuberculosis antigen CFP10[J].Infect Immun,2008,76(9):4199.
    [32] 张海,师长宏,王丽梅,等.表达结核分枝杆菌ESAT6-CFP10融合蛋白DNA疫苗免疫原性[J].第四军医大学学报,2007,28(6):489.
    [33] WANG QM,KANG L,WANG XH.Improved cellular response elicited by a ubiquitin-fused Esat6 DNA vaccine against Mycobacterium tuberculosis[J].Microbiol Immunol,2009,53(7):384.
    [34] HUYGEN K.On the use of DNA Vaccines for the prophylaxis of mycobacterial diseases[J].Infect Immun,2003,71(4):1613.
    [35] JATHOUL AP,HOLEY JL,GARMORY HS.Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters[J].Vaccine,2004,22(29/30):3942.
    [36] CHINSANGARAM J,BEARD C,MASON PW,et al.Antibody response in mice inculated with DNA expressing foot- and-mouth disease virus capsid proteins[J].J Virol,1998,72(5):4454.
    [37] COBAN C,ISHII KJ,GURSEL M,et al.Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors[J].J Leukoc Biol,2005,78(3):647.
    [38] KOZAK M.Recognition of AUG and alternative initiator codons is augmented by G in position +4 but is not generally affected by the nucleotides in positions +5 and +6[J].EMBO J,1997,16(9):2482.
    [39] KRAMMER F,SCHINKO T,MESSNER P,et al.Influenza virus-like particles as an antigen-carrie-r platform for the ESAT-6 epitope of Mycobacterium tuberculosis[J].J Virol Methords,2010,167(1):17.
    [40] KANG SM,SONG JM,QUAN FS,et al.Influenza vaccines based on virus-like particles[J].Virus Res,2009,143(2):140.
    [41] BANGARI DS,MITTAL SK.Development of nonhuman adenoviruses as vaccine vectors[J].Vaccine,2006,24(7):849.
    [42] MU J,JEYANATHAN M,SMALL CL,et al.Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis[J].Mol Ther,2009,17(6):1093.
    [43] ZABOLOTNYKH NV,VINOGRADOVA TI,STUKOVA MA,et al.The effectiveness of influenza vectors expressing the protective mycobacterial antigen ESAT-6 in the complex therapy of generalized tuberculosis in mice[J].Probl Tuberk Bolezn Legk,2008,(12):30.
    [44] SCRIBA TJ,TAMERIS M,MANSOOR N,et al.Modified vaccinia Ankara-expressing Ag85A,a novel tuberculosis vaccine,is safe in adolescents and children,and induces polyfunctional CD4+T cells[J].Eur J Immunol,2010,40(1):279.
    [45] LAKEY DL,VOLADRI RK,EDWARDS KM,et al.Enhanced production of recombinant Mycobacterium tuberculosis antigens in Escherichia coli by replacement of low-usage codons[J].Infect Immun,2000,68(1):233.
    [46] KO HJ,KO SY,KIM YJ,et al.Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B[J].Infect Immun,2005,73(9):5666.
    [47] CHONGHONG S,HAI Z,LIMEI W,et al.Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin2 fusion gene[J].Tuberculosis(Edinb),2009,89(1):54.
    [48] 李晖,李榕,钟森.结核病Mtb8.4/hIL-12嵌合基因疫苗免疫保护效果研究[J].免疫学杂志,2007,23(2):139.
    [49] 王庆敏,殷明,章建程,等.泛素-结核抗原融合基因DNA疫苗诱导小鼠较强的细胞免疫应答[J].第二军医大学学报,2007,28(3):261.
    [50] AGGER EM,ROSENKRANDS I,OLSEN AW,et al.Protective immunity totuberculosis with Ag85B-E SAT-6 in a synthetic cationic adjuvant system IC31[J].Vaccine,2006,24(26):5452.
    [51] GARCON N,CHOMEZ P,VAN MECHELEN M.Adjuvant Systems in vaccines:concepts,acievements and perspectives[J].Expert Rev Vaccines,2007,6(5):723.
    [52] AGGER EM,ROSEN KRANDS I,HANSEN J,et al.Cationic liposomes formulated with syntheic mycobacterial cordfactor(CAF01):a versatile adjuvant for vaccines with different immunological requirements[J].PLoS One,2008,3(9):e3116.
    [53] TRIOZZI PL,ALDRICH W,PONNAZHAGAN S.Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists[J].Vaccine,2010,28(50):7837.
    [54] VENUGOPAL PG,NUTMAN TB,SEMNANI RT.Activation and regulation of toll-like receptor (TLRs) by helminth parasites[J].Immunol Res,2009,43(1/3):252.
    [55] 许利耕,陈春英.纳米材料作为重大疾病疫苗载体或佐剂的研究进展[J].科学通报,2012,57(25):2341.
    [56] XU L,LIU Y,CHEN Z,et al.Surface-engineered gold nanorods:Promising DNA vaccine adjuvant for HIV-1 treatment[J].Nano Lett,2012,12(4):2003.
    [57] POWELL TJ,PALATH N,DEROME ME,et al.Synthetic nanoparicle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo[J].Vaccine,2011,29(3):558.
    [58] 蒋青桃,冯旰珠,夏梅,等.结核杆菌ESAT-6抗原Th1优势表位与FL重组纳米疫苗的制备及其特性研究[J].南京医科大学学报,2011,31(5):620.
    [59] DA'DARA AA,SKELLY PJ,FATAKDAWALA M,et al.Comparative efficacy of the Schistosoma mansoni nucleic acid vaccine,Sm23,following microseeding or gene gun delivery[J].Parasite Immunol,2002,24(4):179.
    [60] XU XM,SONG GX,SI JY.Advance in research on DNA vaccine[J].Prog Microbiol Immunol,2002,30(1):65.
    [61] 宋丹,张颖,黄嘉璐,等.电转染技术结合初免后加强免疫策略增强结核杆菌核酸疫苗免疫原性的研究[J].中华微生物学和免疫学杂志,2006,26(2):127.
    [62] 都伟欣,董娜,陈保文,等.结核病新疫苗的免疫毒理学评价方法研究[J].中国防痨杂志,2012,34(3):138.
  • [1] 方芳张爱霞江京娣何小燕汪洪涛吕静竹钱中清 . 脂多糖对结核病患者外周血单核细胞Toll样受体4表达及细胞内活性氧产生的影响. 蚌埠医学院学报, 2016, 41(4): 431-433. doi: 10.13898/j.cnki.issn.1000-2200.2016.04.003
    [2] 张云凤 . 精细的护理干预在矽肺合并结核患者中的应用效果. 蚌埠医学院学报, 2014, 39(9): 1309-1310.
    [3] 高峰 . 食管癌研究现状综述. 蚌埠医学院学报, 2010, 35(6): 645-648.
    [4] 马丽娜 . 结核分枝杆菌疫苗研究进展. 蚌埠医学院学报, 2005, 30(2): 184-185.
    [5] 唐样王宜君王璐瑶宋雪 . 通过抑制氧化应激损伤治疗炎症性肠病的前景展望. 蚌埠医学院学报, 2024, 49(1): 137-141. doi: 10.13898/j.cnki.issn.1000-2200.2024.01.031
    [6] 冯敏董淮富 . S100B蛋白在新生儿缺氧缺血性脑病诊断和预后判断中的研究进展. 蚌埠医学院学报, 2012, 36(11): 1396-1399.
    [7] 方强 . 猪囊尾蚴病疫苗研究进展. 蚌埠医学院学报, 2006, 31(2): 209-211.
    [8] 王安生刘学刚 . 肺血减少型先天性心脏病远端肺血管发育不良的病理学研究现状. 蚌埠医学院学报, 2010, 35(4): 432-433.
    [9] 彭美玉李柏青 . 结核分枝杆菌蛋白抗原T细胞表位的研究进展. 蚌埠医学院学报, 2011, 36(4): 421-426.
    [10] 高自清 . 糖尿病性黄斑水肿的激光治疗. 蚌埠医学院学报, 2005, 30(3): 280-282.
    [11] 李英欣史东辉 . 人莱姆病的实验室诊断方法的现状. 蚌埠医学院学报, 2006, 31(2): 218-219.
    [12] 张莉石建华项平 . KCNQ1基因与2型糖尿病发病关系的研究进展. 蚌埠医学院学报, 2010, 35(5): 539-541.
    [13] 孔德华王爱玲 . 肥厚型心肌病基因型与表现型研究进展. 蚌埠医学院学报, 2010, 35(7): 753-756.
    [14] 刘继松方勇 . 氧化应激和糖尿病创面的延迟愈合. 蚌埠医学院学报, 2010, 35(7): 756-757.
    [15] 王冉张晓梅 . 人促甲状腺激素受体及其抗体与Graves病关系研究进展. 蚌埠医学院学报, 2013, 37(4): 505-509.
    [16] 杨静静张晓梅 . 双C方案治疗糖尿病的临床研究进展. 蚌埠医学院学报, 2013, 37(2): 240-243.
    [17] 瞿色华董淮富 . 新生儿缺氧缺血性脑病生物标志物的研究现状. 蚌埠医学院学报, 2014, 38(5): 691-694.
    [18] 路改英王启之 . 炎症性肠病与TLR/MyD88信号通路研究进展. 蚌埠医学院学报, 2012, 36(1): 116-118.
    [19] 王媛媛谢虹 . 血糖指数、血糖负荷在2型糖尿病饮食教育中的应用进展. 蚌埠医学院学报, 2015, 40(2): 272-275. doi: 10.13898/j.cnki.issn.1000-2200.2015.02.048
    [20] 陆明陈卫东 . 高同型半胱氨酸血症与糖尿病肾病相关性研究进展. 蚌埠医学院学报, 2009, 34(3): 272-275.
  • 加载中
计量
  • 文章访问数:  4597
  • HTML全文浏览量:  480
  • PDF下载量:  119
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-12-25

结核病DNA疫苗研究进展

    作者简介: 薛玉芹(1985-),女,硕士研究生.
  • 蚌埠医学院病原生物学教研室, 感染与免疫安徽省重点实验室, 安徽蚌埠 233030
基金项目:  国家自然科学基金项目(30600518/C030112)
参考文献 (62)

目录

    /

    返回文章
    返回